


Syneron
Medical Ltd.

Investor
Presentation

April 2012



Science. Results. Trust.

$$\vec{B} d\vec{l} = \mu_0 \sum I_i$$
$$L = 10 \log \frac{I}{I_0}$$
$$P = \frac{\vec{F}}{\Delta S} = \frac{m \Delta \vec{v}}{\Delta S \Delta t}$$
$$P = U$$

Safe Harbor For Forward Looking Statements

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

Investment Highlights

- Global leader in aesthetic devices with 35% worldwide market share¹
- Platform aesthetic company with largest worldwide sales, distribution and service network across 90 countries
- Comprehensive product portfolio with significant recurring revenue and multiple high growth opportunities, including body shaping and skin lightening
- Double digit revenue growth and margin expansion in profitable PAD segment; investing in EBU segment - \$2B+ market opportunity
- ~\$228 million revenue² (29% recurring³); \$171 million in cash (no debt)⁴; significant tax advantages

1 – Based on US publicly traded companies listed here (SLTM, CYNO, PMTI, CUTR, ZLTQ);

2 – Trailing twelve month revenue

3 – Based on 4Q 2011 results in PAD segment

4 – December 31, 2011 Balance Sheet


Leading Aesthetic Industry

Applying technology, infrastructure and expertise to drive leadership in all aesthetic categories

Professional Aesthetic Devices



Emerging Business Units



Breadth and Depth of Technologies

Electro-Optical Synergy (elōs)


- Proprietary technology – first and only combination of bi-polar radio frequency (RF) and optical energy (laser or light)
- Provides safe, controllable, and consistent results with enhanced penetration
- Optimal home-use profile

Candela Lasers

- 40 years of innovation leadership
- Best-in-class laser products

Additional Core Technologies:

- Ultrasound
- Fractional RF
- Skin Lightening
- Teeth Whitening



Delivering Value to the Customer

- Differentiated products with clinical validation
 - 100+ patents granted with 200 pending
 - 100+ studies demonstrating efficacy across indications
 - 100+ clinical studies, publications, and presentations underway
 - Over 700 scientific papers published
 - Strong credibility with thought-leaders
 - Continue acquiring innovative technologies
- Address key customer and patient demands to drive procedure volume
- Superior global customer service and product support

Science. Results. Trust.

Drivers of Market Growth


- Increased global awareness – economic recovery
- Growing acceptance of cosmetic procedures
- Improved efficacy of non-invasive procedures
- Growing middle class in high growth markets (China, Brazil)
- Longer average life expectancy - attracting baby boomers
- Social media / celebrity culture - younger patients



Expanding revenue and profit opportunities

Positioned to Outgrow the Industry

- Strongest industry position in largest and fastest growing Professional Aesthetic Device market segments – #1 or #2 position in each market segment
- Complementary products for dermatologists, plastic surgeons and non-core customers

Procedure	2013 (projected volume)	CAGR (2008 - 2013)	Syneron and Candela Products
Fractional Skin Rejuvenation	3,567,000	15.8%	eTwo™ eMatrix™
Skin Rejuvenation	2,889,000	8.5%	ePrime™ CO ₂ RE™
Cellulite Reduction (Body Contouring)	1,784,000	19.5%	VelaShape® VelaShape®II VelaSmooth Pro™  <small>ULTRASHAPE® The Shape of Things to Come</small>
Hair Removal	9,365,000	13.0%	GentleLase Pro™ eLase™
Skin Tightening	1,226,000	21.8%	
Vascular Lesion Removal	1,003,000	9.4%	Vbeam Perfecta® GentleMax Pro®
Pigment Lesion Removal	892,000	10.2%	
Tattoo Removal	669,000	12.8%	Alex TriVantage®

* Source: U.S. markets for laser, light, and energy devices 2009 Millennium Research

Uniquely Positioned in High Growth Markets

Asia-Pacific growth
greater than 25%



Latin America /
Hispanic growth
greater than 15%




Product range for
all age groups and
skin types



Source: American Society for Aesthetic Plastic Surgery (ASAPS) 2009 Insight / Windover 2006, ASDS 2007 MedTech

Unmatched Global Footprint & Distribution



- Global infrastructure provides agility and flexibility
 - Extensive and superior channel to market capability in over 90 countries
 - Rapidly deploying resources to high growth markets
- Unparalleled global distribution, service, and support capabilities across product segments
 - Direct presence in 13 key markets
 - Direct sales enhance customer relationships, drive service revenue and increase profitability

Case Study: Consumable Business Model

- Pioneering new treatment categories
- Clinically proven efficacy with high patient satisfaction with less downtime
- Growth opportunities with high recurring revenue and margins (consumables)

eTwo™


Sublative Rejuvenation

- For reduction in wrinkles, acne, and scars
- A safer & more effective fractional alternative specifically for ethnic skin
- Sublime applicator for deep dermal remodeling
- Consumable tip model
- Little to no patient downtime & consistent results



Body Contouring Market Opportunity

- The overall obese population in the U.S. could rise to more than 70 million by 2015, with nearly 2.3 billion overweight globally
- The World Health Organization estimates that >70% of European adults (55-64 years of age) are obese or overweight
- More than one-third of U.S. adults (35.7%) are obese



Majority of patients seek non-invasive procedures such as UltraShape's focused ultrasound and Syneron's VelaShape body shaping

Major Growth Opportunity– Body Contouring

- Worldwide market for non invasive body contouring techniques estimated at \$440M with projected annual growth of >15%
- Complimentary technologies - creates sales bundling - technology integration opportunities

VelaShape® II



- Clear leader in non-invasive body shaping and cellulite treatment
- Tightens collagen fibers surrounding fat cells
- 7,000+ installed base to cross-sell UltraShape
- Significant worldwide consumer and customer name brand recognition
- Consumable business model
- Treatment times are significantly shorter than other fat destructive technology (*pay for pulse business model*)
- Pain-free with rapid results
- Leverage Syneron's market position
- UltraShape's Vertical Dynamic Focus (VDF™) allows selective non-thermal destruction of fat cells in various depths of the fat tissue


Strategic Acquisition



- Acquisition of all assets including patent portfolio for approximately \$3.6m in cash
- Innovative transdermal drug delivery technology base on RF-MicroChannels™
- Clinically proven to stimulate skin rejuvenation and increase penetration of cosmetic compounds to targeted layers of skin
- Unique IP and consumable strengthens current fractional RF offering and creates a higher barrier to entry
- Technology can be utilized in both PAD and Home-Use markets



Building an Aesthetic Platform Company



Innovative Technology and Intellectual Property

Leadership Opportunity: High Growth Emerging Markets

Significant growth opportunities with high margin, recurring revenue products

Home Use Devices (HUD)

- Projected \$350M+ market in 2013 with 27% 5-year CAGR ^{1,2}
- Increased consumer desire for treatments at home
- Includes facial/skin rejuvenation, hair removal

Teeth Whitening and Fluorination

- Blockbuster global market ~\$5.5B
- Methods - white strips, professional treatments, whitening trays/gels
- Treatments - more effective and last longer

Skin Lightening

- Extraordinary global market ~\$14B (~\$1B professional market)
- Skin lightening widely used in Asia (~90% of market)
- Daily use product – major recurring revenue opportunity

1 – Manufacturer revenues are calculated as 50% of retail sales. 2 – Source: Medical Insight, Oct 2009

Home Use Devices



"mē" Home Use Hair Removal System

- Dual action: immediate & permanent hair removal performed simultaneously
- More effective on light colored hair due to elōs technology & epilation option
- Suitable for nearly all skin types
- Fastest performance on the market – 4X faster



Tanda Pearl Teeth Whitening Home Use System

- Breakthrough patented ionic technology delivers the fastest whitening with minimal sensitivity
- Pivotal clinical study (120 patients) demonstrated superior results vs. top competitive product for both whitening and shortest time
- Q1 2012 launch in the prestige retail consumer market (Nordstrom, Neiman Marcus, Bloomingdales and more)



Home Use Devices



ēlos Skin Rejuvenation Home Use Device

- Strategic partnership with Procter & Gamble for co-branded skin rejuvenation product
- Designed with strong focus on exceptional results, ease-of-use and safety controls



Tanda LED Home Use Devices

- Clinically validated LED light therapy is complementary to Syneron's technology
- Multi-pronged distribution model including premium retailers and healthcare professionals
- Tanda product categories: Acne Solution and Anti-Aging Solutions



Neiman Marcus

SEPHORA

bloomingdales

NORDSTROM


elure™ Advanced Skin Lightening

- *Allure Magazine* named elure™ #1 Best of Beauty Breakthrough of 2011
- Provides superior efficacy and speed of action
 - Enzyme decomposes melanin – provides results in 7 days (vs. 4-6 weeks with hydroquinone, which also causes significant irritation)
- Patent-protected until 2023
- Strong clinical results and intellectual property
- Recurring revenue and high GM product
- Expect to obtain regulatory approval in major Asian markets 2H 2012



Financial Strength

- \$171 million cash, no debt
- Expanding recurring revenue (29% of PAD segment revenue)
- Improving margins
- Ongoing operating expense reductions
- Clear market leader with 35% market share¹



¹ – Based on US publicly traded companies only

Fourth Quarter 2011 Highlights

- Revenue of \$61.0 million, up 14% YoY
 - International revenue of \$40.1 million, up 14% YoY
 - North America revenue of \$20.9 million, up 15% YoY
 - Significant cross-selling revenues
 - Service and consumables represented 29% of PAD segment revenue
- Gross margin of 55.0%¹, up from 53.8% in 3Q11
- Operating profit in Professional Aesthetic Device business of \$5.6 million¹; Continued investment in EBU
- Emerging Business Units revenue of \$6.0 million, up 336% YoY and representing ~10% of total revenue
- Net income of \$1.1 million¹, or \$0.03 per share vs. net income of \$3.6 million, or \$0.10 per share prior year

¹ – Non-GAAP figures exclude stock-based compensation, amortization and merger related expenses, and Palomar settlement expenses and associated legal fees

Investment Highlights

- Global leader in aesthetic devices with 35% worldwide market share¹
- Financially strong with diversified revenue streams and improving margins
- Increasing recurring revenue through consumable business model
- Double digit revenue growth and margin expansion in profitable PAD segment
- Investing in EBU segment and exciting growth markets

¹ – Based on US publicly traded companies listed here (SLTM, CYNO, PMTI, CUTR, ZLTQ);



Thank You

To lead and drive the widespread accessibility of trustworthy aesthetic products to the general public